Clinical Spectrum, Quality of Life, BRAF Mutation Status and Treatment of Skin Involvement in Adult Langerhans Cell Histiocytosis
Langerhans cell histiocytosis is a rare histiocytic disorder for which skin involvement and management are poorly described in adults. The aim of this retrospective monocentric study in a national reference centre is to describe the clinical characteristics, quality of life, BRAF mutation status and...
Saved in:
Main Authors: | Etienne Crickx (Author), Jean-David Bouaziz (Author), Gwenaël Lorillon (Author), Mathilde de Menthon (Author), Florence Cordoliani (Author), Emmanuell Bugnet (Author), Martine Bagot (Author), Michel Rybojad (Author), Samia Mourah (Author), Abdellatif Tazi (Author) |
---|---|
Format: | Book |
Published: |
Medical Journals Sweden,
2017-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of BRAF inhibitor (Vemurafenib) in a child with Refractory Langerhans cell histiocytosis
by: Anil Sharma, et al.
Published: (2017) -
Targeted therapy- Vemurafinib in BRAF V600E positive Langerhan cell histiocytosis
by: Mohammed Naseer, et al.
Published: (2017) -
Targeted Therapy- Vemurafinib in BRAF V600E positive langerhan cell histiocytosis
by: Mohammed Naseer, et al.
Published: (2017) -
BRAF- and MAP2K1-negative multisystem langerhans cell histiocytosis in an elderly patient
by: Rohit Kothari, et al.
Published: (2023) -
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
by: Sara V. Bates, et al.
Published: (2013)